Video

Dr. West on the Gefitinib Advanced NSCLC Trial

Dr. Jack West Swedish Cancer Institute on the Gefitinib Advanced non-small cell lung cancer Trial

H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, discusses findings from a phase III, randomized, multicenter, parallel group study (NCT00770588) that examined the efficacy of gefitinib as a maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC). The trial discovered that progression free survival was much longer in Chinese patients receiving gefitinib than those receiving placebo.

Related Videos
Bhavana Pothuri, MD
Kristen Spencer, DO
Laurence Albigès, MD, PhD
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Joshua K. Sabari, MD
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
MATT WAGAR, MD